Back to News
Market Impact: 0.3
Encoded Therapeutics Raises $275 Million in Series F Financing to Advance ETX101 Through Pivotal Development and Accelerate its Precision Genetic Medicines Neurology Pipeline
Source: Business Wire
Private Markets & VentureHealthcare & Biotech
Encoded Therapeutics raised $275 million in a Series F financing to advance its precision genetic medicines pipeline for neurological diseases. The sizable private funding round strengthens the biotech's capacity to fund clinical development, though the release provides no further terms, valuation, or program-specific milestones.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
More News
- Brookfield to open Qatar office as it expands Middle East operations
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Fact vs. fiction: Doctors share whether peptides are safe and effective